Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Flying without a Real ID? That'll soon cost you $45, TSA says. - 2Director of Swiss hospital describes the rush to treat the injured from Alpine resort bar fire
- 3Foot fossil discovery could reshape human evolutionary history
- 4Inside The Design-Forward Wellness Hotel Marking A New Chapter In Medellín
- 5Artemis II shares new lunar images while more than halfway to the moon
- Lecturer who called Israel a terrorist state to remain Plaid Cymru candidate
- I visited the largest collection of public telescopes in the US in Oregon's high desert, and the dark skies blew me away
- One killed, several injured in Iran missile barrage on southern, central Israel
- Newly Built Sichuan Hydropower Bridge Collapses Into River Months After Opening
- OPEC’s No. 2 Producer Burns Its Own Gas—Then Buys Iran’s
- Top 10 Arising Advances That Will Shape What's in store
- Startled Venezuelans express relief but also fear after Maduro arrest
- The most effective method to Make a Dazzling Site in 5 Basic Advances
- Everything you should know before booking a trip to Spain
